Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4A11 | Q02928 | 7/20 | 0.51 |
| ▸ | CYP4F2 | P78329 | 6/20 | 0.51 |
| ▸ | PPARA | Q07869 | 2/20 | 0.46 |
| ▸ | PTPRB | P23467 | 3/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.37 |
| ▸ | PTPRA | P18433 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | PTPRC | P08575 | 1/20 | 0.36 |
| ▸ | PTPRG | P23470 | 1/20 | 0.36 |
| ▸ | ACP1 | P24666 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6741713 | 0.86 | KMT2A (0.41) | CYP4A11CYP4F2PTPRBCA2NPC1 | |
| SCHEMBL11063035 | 0.85 | SAE1 (0.47) | PTPRBCA2NPC1HPGDRAB9A | |
| SCHEMBL19707373 | 0.78 | RAB9A (0.53) | NPC1HPGDRAB9AMAPT | |
| SCHEMBL3656294 | 0.77 | CYP4A11 (0.54) | CYP4A11CYP4F2PPARACA2CA1 | |
| SCHEMBL8880437 | 0.77 | CYP4A11 (0.54) | CYP4A11CYP4F2PPARAPTPRBCA2 | |
| SCHEMBL19707314 | 0.76 | POLB (0.54) | PPARANPC1RAB9AMAPT | |
| SCHEMBL11333348 | 0.76 | ELANE (0.48) | NPC1HPGDRAB9AMAPT | |
| SCHEMBL9756879 | 0.75 | MAPT (0.59) | PTPRBPTPN2PTPN1PTPRAMAPT | |
| SCHEMBL6743375 | 0.75 | PTPRB (0.43) | PPARAPTPRBNPC1RAB9APTPN2 | |
| SCHEMBL6861392 | 0.74 | CTRB1 (0.39) | PPARAPTPRBPTPN2PTPN1PTPRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6790865-B2 | 2-HYDROXY-2-(4-HYDROXYPHENYL)-1-METHYLETHYL)AMINO)ETHYL)PHENOXY OR IMINO)-2-METHYLPROPIONIC ACID DERIVATIVE EXCELLENT BETA 3-ADRENOCEPTOR STIMULANTS | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2004-09-14 | — | — | US | disclosed |
| EP-1072583-B1 | 2-METHYLPROPIONIC ACID DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | KISSEI PHARMACEUTICAL (JP) | 2004-09-01 | — | — | EP | disclosed |
| US-6696489-B1 | PHENOLIC AND PHENYLAMINO SUBSTITUENTS; BETA 3-ADRENOCEPTOR AGONISTS; OBESITY, HYPERGLYCEMIA, INTESTINAL HYPERMOTILITY, POLLAKIURIA, URINARY INCONTINENCE, DEPRESSION | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2004-02-24 | — | — | US | disclosed |
| US-20030166719-A1 | 2-hydroxy-2-(4-hydroxyphenyl)-1-methylethyl)amino)ethyl)phenoxy or imino)-2-methylpropionic acid derivative excellent beta 3-adrenoceptor stimulants | KISSEI PHARMACEUTICAL CO., LTD. | 2003-09-04 | — | — | US | disclosed |
| EP-1072583-A1 | 2-METHYLPROPIONIC ACID DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | Kissei Pharmaceutical Co., Ltd. (JP) | 2001-01-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166719-A1 | 2-hydroxy-2-(4-hydroxyphenyl)-1-methylethyl)amino)ethyl)phenoxy or imino)-2-methylpropionic acid derivative excellent beta 3-adrenoceptor stimulants | ADRB1, ADRB2, ADRA2A | CYP4A11 698/4885CYP4F2 1650/4885PPARA 323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.